GRANT ERDEL

HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.

HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2016 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2016 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.

Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."

Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.

Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."

Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.

Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.

Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.

Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.

Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to and implementation of the Affordable Care Act, including biologics; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; S.2295, Patient Safety & Generic Labeling Improvement Act; drug shortages; Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.

Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.

Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; H.R.5, Help Efficient Accessible Low-Cost Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act

Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.

H.R.5698, legislation temporarily suspending the duty on S-(2-benzothiazolyl)-2-(2-amino-thiazol-4-yl)-2-acetoxyimino thiocetate (Thioester).